免疫隐蔽的VP28结合氨酸纳米颗粒用于增强和可逆抗凝固
Hussein Reda Hussein1,2, Chia-Yu Chang1, Yini Zheng3
1Department of Biological Science and Technology, National Yang Ming Chiao Tung University, 30068 Hsinchu, Taiwan.
Nanotechnology
|January 23, 2024
概括
一个新的VP28-氨酸纳米粒子提供了改善的抗凝和延长的循环时间. 这种氨酸衍生物显示了氨酸诱导血栓塞缩症 (HIT) 的风险降低,并且是一种潜在的更安全的治疗选择.
科学领域:
- 生物材料科学 生物材料科学
- 药理学 药理学是指药理学的学科.
- 纳米技术 纳米技术
背景情况:
- 氨酸是重要的抗凝剂,但可能导致血液循环减少和危险的氨酸诱导的血栓塞缩症 (HIT).
- 将肝素与隐形生物分子 (如病毒囊蛋白VP28) 相结合,可以克服这些限制.
研究的目的:
- 开发和描述一种新型的氨酸结合纳米粒子 (VP28-氨酸).
- 在动物模型中评估其免疫性,抗凝效,血小板效应和HIT风险.
主要方法:
- 重组病毒囊蛋白 (VP28) 与肝素结合,形成VP28-肝素纳米粒子.
- 鉴定包括尺寸分析和免疫性,抗凝血,血小板计数和HIT诱导 in vivo的评估.
- 还测试了用蛋白胺硫酸盐治疗抗凝剂的逆转作用.
主要成果:
- VP28-氨酸纳米颗粒是非免疫原的,具有长期循环的最佳尺寸.
- 没有观察到血小板计数或死亡率的显著降低,这表明HIT风险降低.
- 与未分离的氨酸相比,VP28-氨酸显示出更强的抗凝作用 (2.2倍PT) 和更长的持续时间.
结论:
- VP28-氨酸纳米颗粒代表了传统氨酸的有希望的,更安全的替代品.
- 这种新的配方克服了诸如流通时间缩短和HIT风险等限制.
- 这种先进的肝素衍生物的进一步治疗应用是有必要的.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525


